EAST Search History
`
`1117 1149
`
`L118 Ii87
`
`L119 11247
`
`L120 138
`
`L121 1141
`
`L122 \ 182
`
`L123 ! 39
`
`L124 |o
`
`L125 5 687
`
`L126 1127
`\
`L129 1157
`
`L130
`
`I L114 and (estradiol NEAR
`| flux)
`
`j L112 and (estradiol NEAR
`| flux)
`
`j L119 and estradiol
`
`s L119 and transdermal
`
`ilUS-PGRUB; USPAT;
`! USOCR; FPRS; EPO;
`(jPO; DERWENT
`I US-PGPUB; USPAT;
`I USOCR; FPRS; EPO;
`I JPO: DERWENT
`||MANTELLEin. and JUAN.in. I US-PGPUB; USPAT;
`I USOCR; FPRS; EPO;
`I JPO: DERWENT
`I US-PGPUB; USPAT;
`I USOCR; FPRS; EPO;
`j JPO: DERWENT
`I US-PGPUB; USPAT;
`I USOCR; FPRS; EPO;
`| JPO; DERWENT
`I US-PGPUB; USPAT;
`I USOCR; FPRS; EPO;
`! JPO: DERWENT
`mm:
`| US-PGPUB; USPAT;
`j USOCR; FPRS; EPO;
`! JPO: DERWENT
`1 USPAT; USOCR
`
`! Kanios.in. and David.in.
`
`! L122 NOT L119
`
`!|(11/245097).APR
`
`j L112 and ("dipropylene
`' glycol" oleyl)
`! L114 and ("dipropylene
`! glycol" oleyl)
`!j(("MANTELLE") near3
`I ("Juan")).INV.
`!| 12/216811
`
`I USPAT; USOCR
`
`j USPAT; USOCR
`
`US-PGPUB; USPAT;
`IUSOCR
`i US-PGPUB; USPAT;
`I USOCR; FPRS; EPO;
`j JPO: DERWENT
`I USPAT; USOCR
`
`L131 ! 1
`
`! (12/216811).APR
`
`L133 ill5907 !|A61 K31/565.cpc.
`
`OR
`
`OFF
`
`IfOR
`
`iiOFF
`
`l[OR
`
`IIOFF
`
`IfOR
`
`IjOFF
`
`I OR
`
`IiOFF
`
`I OR
`
`I OFF
`
`! OR
`
`!OFF
`
`!OFF
`
`![OFF
`
`!OFF
`
`!fOFF
`
`IfOFF
`
`12016/08/22j
`| 09:57
`
`i 2016/08/22;
`| 09:57
`
`i 2016/08/22j
`| 09:57
`
`!|2016/08/22!
`109:57
`||
`
`12016/08/22!
`109:57
`jj
`
`i 2016/08/22!
`| 09:57
`
`LUUUUUUUUUUUUU;
`s 2016/08/22!
`j 09:57
`
`2016/08/22!
`09:57
`s 2016/08/22!
`I 09:57
`12016/08/22!
`09:57
`!|2016/08/22!
`|l0:03
`|
`!|2016/08/22!
`jj
`! 10:09
`
`! OR
`
`! OR
`
`!OR
`
`! OR
`
`IOR
`
`!OR
`
`! AND
`
`!OFF
`
`s 2016/08/22!
`J[l0:09
`! OFF 112016/08/22!
`.
`j 10:15
`'
`
`US-PGPUB; USPAT;
`I USOCR; FPRS; EPO;
`j JPO: DERWENT
`US-PGPUB; USPAT;
`I USOCR; FPRS; EPO;
`j JPO: DERWENT
`A
`mi; Lmmmmmmmum: mmmm mmmm mmmmmmmmmmmmmmmmmmimm: mm: mmmmmmmmmmmmm: mmmmmmm: mmmmm:
`!OFF
`! AND
`| US-PGPUB; USPAT;
`! L133 L134
`L135 | 33
`j USOCR; FPRS; EPO;
`I JPO: DERWENT
`| US-PGPUB; USPAT;
`| USOCR; FPRS; EPO;
`I JPO: DERWENT
`
`L134 |4711
`
`! A61 K9/70.cpc.
`
`! 2016/08/22!
`h0:15
`:
`!
`:
`
`i 2016/08/22!
`h0:15
`'
`
`! AND
`
`!|OFF
`
`L136 | 8
`
`![LI 35 and estradioi
`
`! AND
`
`!OFF
`
`s 2016/08/22!
`j 10:16
`
`8/22/2016 10:22:21 AM
`C:\ Users\ mjavier\ Documents\ EAST\ Workspaces\ 13553972.wsp
`
`EASTSearchHistory.l3553972_ Accessible Version.htm[8/22/2016 10:22:26 AM]
`
`
` 

 
`   
`0428 
`
`MYLAN - EXHIBIT 1035
`Part 2 of 2
`
`

`

`r
`
`kSheet
`
`Substitute for form 1449/PTO
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`Date Submitted: August 2, 2016
`(use as many sheets as necessary)
`of
`1
`1
`
`13553972 - GAU: 1611
`
`PTO/SB/08 (modified
`
`Application Number
`Filing Date
`First Named Inventor
`Art Unit
`Examiner Name
`Attorney Docket Number
`
`Complete if Known
`13/553972
`7/20/2012
`Juan Mantelle
`1611
`Melissa L. Javier
`041457-0992
`
`y
`
`Examiner
`Initials*
`
`Cite
`No.
`
`Document Number
`
`Number-Kind Code2 (if
`known)
`
`U.S. PATENT DOCUMENTS
`
`Publication Date
`MM-DD-YYYY
`
`Name of Patentee or Applicant of
`Cited Document
`
`Pages, Columns, Lines,
`Where Relevant
`Passages or Relevant
`Figures Appear
`
`Examiner
`Initials*
`
`Cite
`No.1
`
`UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS
`U.S. Patent Application
`Document
`Serial Number-Kind Cod?
`(if known)
`
`Filing Date of
`Cited Document
`MM-DD-YYYY
`
`Name of Patentee or Applicant of
`Cited Document
`
`Pages, Columns, Lines,
`Where Relevant
`Passages or Relevant
`Figures Appear
`
`Examiner
`Initials*
`
`Cite
`No.1
`
`Foreign Patent Document
`Country Code^TNumber4"
`Kind Code5 (if known)
`
`Publication Date
`MM-DD-YYYY
`
`Name of Patentee or
`Applicant of Cited Documents
`
`Pages, Columns, Lines,
`Where Relevant
`Passages or Relevant
`Figures Appear
`
`T6
`
`FOREIGN PATENT DOCUMENTS
`
`Examiner
`Initials*
`
`Cite
`No.1
`
`A1
`
`NON PATENT LITERATURE DOCUMENTS
`Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the
`item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue
`number(s), publisher, city and/or country where published.
`MANTELLE, "DOT Matrix® Technology," Modified-Release Drug Delivery Technology, Rathbone et al.,
`eds., Chapter 30, pp. 405-415, May 28, 2008.
`
`f
`
`A2
`
`Office Action issued on 05/05/2016 in application number 14/024,985 (US 2014-0200530)
`
`A3
`
`A4
`
`Notice of Allowance issued on 10/02/2015 in application number 14/024,985 (US 2014-0200530)
`
`Office Action issue on 04/29/2016 in application number 14/738,255 (US 2015-0272905)
`
`A5
`
`Office Action issue on 10/26/2015 in application number 14/738,255 (US 2015-0272905)
`
`p
`Examiner
`Signature
`ta
`4820-3175-0709.1
`
`/MELISSA L JAVIER/
`
`Date
`Considered
`
`08/22/2016
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/M.L.J/
`
`0429 
`
`

`

`Application/Control No.
`Issue Classification 13553972
`Examiner
`
`MELISSA JAVIER
`
`Applicant(s)/Patent Under Reexamination
`
`MANTELLE, JUAN
`
`Art Unit
`
`1611
`
`565
`
`10
`
`i
`i
`i
`i
`i
`32
`i 0014
`i
`
`7069
`
`7061
`
`CPC
`Symbol
`
`A61K
`
`A61K
`
`A61K
`
`A61K
`
`A61K
`
`A61K
`
`9
`
`9
`
`31
`
`47
`
`47
`
`9
`
`CPC Combination Sets
`Symbol
`
`1
`i
`
`1
`1
`
`(Assistant Examiner)
`/MELISSA JAVIER/
`Examiner.Art Unit 1611
`
`(Primary Examiner)
`
`U.S. Patent and Trademark Office
`
`F
`
`Type
`
`Version
`
`2013-01-01
`
`2013-01-01
`
`2013-01-01
`
`2013-01-01
`
`2013-01-01
`
`2013-01-01
`
`Type
`
`Set
`
`Ranking
`
`Version
`
`Total Claims Allowed:
`
`21
`
`(Date)
`
`08/22/2016
`
`O.G. Print Claim(s)
`
`O.G. Print Figure
`
`(Date)
`
`1
`
`None
`
`Part of Paper No. 20160822
`
`0430 
`
`

`

`Application/Control No.
`Issue Classification 13553972
`Examiner
`
`MELISSA JAVIER
`
`Applicant(s)/Patent Under Reexamination
`
`MANTELLE, JUAN
`
`Art Unit
`
`1611
`
`US ORIGINAL CLASSIFICATION
`
`INTERNATIONAL CLASSIFICATION
`
`CLASS
`
`SUBCLASS
`
`CLAIMED
`
`NON-CLAIMED
`
`CROSS REFERENCE(S)
`
`CLASS
`
`SUBCLASS (ONE SUBCLASS PER BLOCK)
`
`A
`
`A
`
`6
`
`6
`
`1
`
`1
`
`K
`
`K
`
`31 / 565 (2006.01.01)
`
`9/70 (2006.01.01)
`
`(Assistant Examiner)
`/MELISSA JAVIER/
`Examiner.Art Unit 1611
`
`(Primary Examiner)
`
`U.S. Patent and Trademark Office
`
`Total Claims Allowed:
`
`21
`
`(Date)
`
`08/22/2016
`
`O.G. Print Claim(s)
`
`O.G. Print Figure
`
`(Date)
`
`1
`
`None
`
`Part of Paper No. 20160822
`
`0431 
`
`

`

`Application/Control No.
`Issue Classification 13553972
`Examiner
`
`MELISSA JAVIER
`
`Applicant(s)/Patent Under Reexamination
`
`MANTELLE, JUAN
`
`Art Unit
`
`1611
`
`G
`
`Claims renumbered in the same order as presented by applicant
`
`•
`
`CPA
`
`M
`
`T.D.
`
`• R.I .47
`
`Final
`
`Original
`
`Final
`
`Original
`
`Final
`
`Original
`
`Final
`
`Original
`
`Final
`
`Original
`
`Final
`
`Original
`
`Final
`
`Original
`
`Final
`
`Original
`
`1
`
`2
`
`3
`
`4
`
`5
`
`16
`
`2
`
`17
`
`18
`
`19
`
`20
`
`21
`
`12
`
`13
`
`14
`
`17
`
`18
`
`33
`
`34
`
`35
`
`36
`
`37
`
`38
`
`19
`
`20
`
`21
`
`39
`
`40
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`12
`
`13
`
`14
`
`15
`
`16
`
`3
`
`4
`
`5
`
`6
`
`7
`
`8
`
`9
`
`10
`
`11
`
`22
`
`23
`
`24
`
`25
`
`26
`
`27
`
`28
`
`29
`
`30
`
`31
`
`32
`
`1
`
`15
`
`(Assistant Examiner)
`/MELISSA JAVIER/
`Examiner.Art Unit 1611
`
`(Primary Examiner)
`
`U.S. Patent and Trademark Office
`
`Total Claims Allowed:
`
`21
`
`(Date)
`
`08/22/2016
`
`O.G. Print Claim(s)
`
`O.G. Print Figure
`
`(Date)
`
`1
`
`None
`
`Part of Paper No. 20160822
`
`0432 
`
`

`

`Atty. Dkt. No. 041457-0992
`
`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`First Inventor Name:
`
`Juan Mantelle
`
`Title:
`
`Appl. No.:
`
`Transdermal Estrogen Device and Delivery
`
`13/553972
`
`Appl. Filing Date:
`
`7/20/2012
`
`Examiner:
`
`Art Unit:
`
`Melissa L. Javier
`
`1611
`
`Confirmation Number:
`
`3635
`
`REQUEST FOR CONTINUED EXAMINATION (RCE)
`TRANSMITTAL
`
`Mail Stop RCE
`Commissioner for Patents
`P.O.Box 1450
`Alexandria, VA 22313-1450
`
`Commissioner:
`
`This is a Request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the
`above-identified application. This RCE and the enclosed items listed below are being filed prior
`to the earliest of: (1) payment of the issue fee (unless a petition under 37 C.F.R. § 1.313 is
`granted); (2) abandonment of the application; or (3) the filing of a notice of appeal to the U.S.
`Court of Appeals for the Federal Circuit under 35 U.S.C. §141, or the commencement of a civil
`action under 35 U.S.C. §145 or §146 (unless the appeal or civil action is terminated).
`
`4845-4883-6925,1
`
`0433 
`
`

`

`Submission required under 37 C.F.R. §1.114;
`
`[ X ]
`
`Information Disclosure Statement.
`
`[ X ] Form PTO/SB/08 with copies of 9 listed reference(s).
`
`The filing fee is calculated below at the large entity rate:
`
`Claims as
`Amended
`
`Previously
`Paid For
`
`Extra Claims
`Present
`
`RCE Fee 1.17(e):
`
`Atty. Dkt. No. 041457-0992
`
`Rate
`
`Fee Totals
`$1,700.0 = $1,700.00
`
`0
`
`Total Claims:
`
`Independents
`
`13
`
`3
`
`26
`
`5
`
`= 0
`
`= 0
`
`x
`
`x
`
`$80.00 =
`
`$0.00
`
`$420.00 =
`
`$0.00
`
`First presentation of any Multiple Dependent Claims: +
`
`$780.00 =
`
`$0.00
`
`RCE and CLAIMS FEE TOTAL: = $1,700.00
`
`The above-identified fees of $1700.00 are being paid by credit card via EFS-Web.
`
`The Commissioner is hereby authorized to charge any additional fees which may be
`required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to
`Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by the credit
`card payment instructions in EFS-Web being incorrect or absent, resulting in a rejected or
`incorrect credit card transaction, the Commissioner is authorized to charge the unpaid amount to
`Deposit Account No. 19-0741.
`
`4845-4883-6925.1
`
`0434 
`
`

`

`Please direct all correspondence to the undersigned attorney or agent at the address
`indicated below.
`
`Atty. Dkt. No. 041457-0992
`
`lOirx- UB , J Sib
`
`i
`
`Date
`
`FOLEY & LARDNER LLP
`Customer Number: 22428
`(202) 295-4094
`Telephone:
`(202) 672-5399
`Facsimile:
`
`Respectfully submitted,
`
`By
`
`hA
`/•^
`i— '^-7 C_
`Wf?/
`f
`u
`Courtenay C. Brinckerhoff
`Attorney for Applicant
`Registration No. 37,288
`
`4845-4883-6925.1
`
`0435 
`
`

`

`IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
`
`Atty. Dkt. No. 041457-0992
`
`First Inventor Name:
`
`Juan Mantelle
`
`Title:
`
`Transdermal Estrogen Device
`and Delivery
`
`Application No.:
`
`13/553,972
`
`Filing Date:
`
`7/20/2012
`
`Examiner:
`
`Art Unit:
`
`Confirmation No.:
`
`Melissa L. Javier
`
`1611
`
`3635
`
`INFORMATION DISCLOSURE STATEMENT
`UNDER 37 CFR §1.56
`
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`Commissioner:
`
`Applicant submits herewith documents for the Examiner's consideration in accordance
`with 37 CFR §§1.56, 1.97 and 1.98.
`
`Applicant respectfully requests that each listed document be considered by the Examiner
`and be made of record in the present application and that an initialed copy of Form PTO/SB/08
`be returned in accordance with MPEP §609.
`
`The submission of any document herewith is not an admission that such document
`constitutes prior art against the claims of the present application or that such document is
`considered material to patentability as defined in 37 CFR § 1.56(b). Applicant does not waive
`any rights to take any action which would be appropriate to antedate or otherwise remove as a
`competent reference any document submitted herewith.
`
`4823-6143-6221.1
`
`0436 
`
`

`

`Atty. Dkt. No. 041457-0992
`
`TIMING OF THE DISCLOSURE
`The listed documents are being submitted in compliance with 37 CFR § 1.97(b), before
`the mailing of a first Office action after the filing of a RCE.
`
`Although Applicant believes that no fee is required, the Commissioner is hereby
`authorized to charge any additional fees which may be due for this application to Deposit
`Account Number 19-0741.
`
`Respectfully submitted,
`
`Date November 28. 2016
`
`By /Courtenav C. Brinckerhoff/
`
`FOLEY & LARDNER LLP
`Customer Number: 22428
`Telephone:
`(202) 295-4094
`Facsimile:
`(202) 672-5399
`
`Courtenay C. Brinckerhoff
`Attorney for Applicant
`Registration No. 37,288
`
`4823-6143-6221.1
`
`0437 
`
`

`

`Substitute for form 1449/PTO
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`Date Submitted: November 28, 2016
`fuse as many sheets as necessary)
`of
`2
`1
`
`^Sheet
`
`Application Number
`Filing Date
`First Named Inventor
`Art Unit
`Examiner Name
`Attorney Docket Number
`
`Complete if Known
`13/553972
`7/20/2012
`Juan Mantelle
`1611
`Melissa L. Javier
`041457-0992
`
`PTO/SB/08 (modified
`
`y
`
`Examiner
`Initials*
`
`Cite
`No.1
`
`Document Number
`
`Number-Kind Code2 (if
`known)
`
`U.S. PATENT DOCUMENTS
`
`Publication Date
`MM-DD-YYYY
`
`Name of Patentee or Applicant of
`Cited Document
`
`Pages, Columns, Lines,
`Where Relevant
`Passages or Relevant
`Figures Appear
`
`Examiner
`Initials*
`
`Cite
`No.1
`
`UNPUBLISHED U.S. PATENT APPLICATION DOCUMENTS
`U.S. Patent Application
`Document
`Serial Number-Kind Code2
`(if known)
`
`Filing Date of
`Cited Document
`MM-DD-YYYY
`
`Name of Patentee or Applicant of
`Cited Document
`
`Pages, Columns, Lines,
`Where Relevant
`Passages or Relevant
`Figures Appear
`
`Examiner
`Initials*
`
`Cite
`No.1
`
`Foreign Patent Document
`Country Code^Number'''
`Kind Code5 (if known)
`
`Publication Date
`MM-DD-YYYY
`
`Name of Patentee or
`Applicant of Cited Documents
`
`Pages, Columns, Lines,
`Where Relevant
`Passages or Relevant
`Figures Appear
`
`T6
`
`FOREIGN PATENT DOCUMENTS
`
`Examiner
`Initials*
`
`Cite
`No.1
`
`A1
`
`NON PATENT LITERATURE DOCUMENTS
`Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the
`item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue
`number(s), publisher, city and/or country where published.
`TOOLE ET AL., "Evaluation of irritation and sensitisation of two 50 pg/day oestrogen patches,"
`Maturitas, Vol. 43, pp. 257-263, December 2002.
`
`T6
`
`A2
`
`A3
`
`A4
`
`A5
`
`A6
`
`A7
`
`A8
`
`MARTY, "New trends in transdermal technologies: Development of the skin patch, Menorest®,"
`International Journal of Gynecology & Obstetrics, Vol. 52, Suppl. 1, pp. S17-S20, March 1996.
`
`NOVARTIS, "Estraderm®," Prescribing information, June 2004.
`
`NOVARTIS, "Vivelle®," Prescribing information, June 2004.
`
`NOVARTIS, "Vivelie-Dot®," Prescribing information, June 2004.
`
`BAYER HEALTHCARE, "Climara®," Prescribing information, 2007
`
`3M PHARMACEUTICALS, "Menostar™," Prescribing information, June 2004.
`
`WATSON PHARMA, INC., "Alora®," Prescribing information, May 2005.
`
`Examiner
`Signature
`4832-4407-5069.1
`
`Date
`Considered
`
`0438 
`
`

`

`PTO/SB/08 fmodified
`
`Substitute for form 1449/PTO
`INFORMATION DISCLOSURE
`STATEMENT BY APPLICANT
`Date Submitted: November 28, 2016
`
`(use as many sheets as necessary)
`2
`2
`of
`
`kSheet
`
`Application Number
`Filing Date
`First Named Inventor
`Art Unit
`Examiner Name
`Attorney Docket Number
`
`Complete if Known
`13/553972
`7/20/2012
`Juan Mantelle
`1611
`Melissa L. Javier
`041457-0992
`
`Examiner
`Initials*
`
`NON PATENT LITERATURE DOCUMENTS
`Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the
`item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue
`number(s), publisher, city and/or country where published.
`SERONO LABORATORIES, INC., "Esclim®," Prescribing information, August 1998.
`
`Cite
`No.1
`
`A9
`
`y
`
`T8
`
`p
`Examiner
`Signature
`ll
`4832-4407-5069.1
`
`Date
`Considered
`
`0439 
`
`

`

`Electronic Patent Application Fee Transmittal
`
`Application Number:
`
`Filing Date:
`
`13553972
`
`20-Jul-2012
`
`Title of Invention:
`
`TRANSDERMAL ESTROGEN DEVICE AND DELIVERY
`
`First Named Inventor/Applicant Name:
`
`Juan Mantelle
`
`Filer:
`
`Courtenay C. Brinckerhoff
`
`Attorney Docket Number:
`
`041457-0992
`
`Filed as Large Entity
`
`Filing Fees for Utility under 35 USC 111 (a)
`
`Description
`
`Fee Code
`
`Quantity
`
`Amount
`
`Sub-Total in
`USD($)
`
`Basic Filing:
`
`Pages:
`
`Claims:
`
`Miscellaneous-Filing:
`
`Petition:
`
`Patent-Appeals-and-lnterference:
`
`Post-Allowance-and-Post-lssuance:
`
`Extension-of-Time:
`
`0440
`
`

`

`Description
`
`Fee Code
`
`Quantity
`
`Amount
`
`Sub-Total in
`USD($)
`
`Miscellaneous:
`
`RCE- 2ND AND SUBSEQUENT REQUEST
`
`1820
`
`1
`
`1700
`
`1700
`
`Total in USD ($)
`
`1700
`
`0441 
`
`

`

`Electronic Acknowledgement Receipt
`
`EFSID:
`
`Application Number:
`
`27619812
`
`13553972
`
`International Application Number:
`
`Confirmation Number:
`
`3635
`
`Title of Invention:
`
`TRANSDERMAL ESTROGEN DEVICE AND DELIVERY
`
`First Named Inventor/Applicant Name:
`
`Juan Mantelle
`
`Customer Number:
`
`22428
`
`Filer:
`
`Courtenay C. Brinckerhoff/Christine Arthur
`
`Filer Authorized By:
`
`Courtenay C. Brinckerhoff
`
`Attorney Docket Number:
`
`Receipt Date:
`
`Filing Date:
`
`Time Stamp:
`
`041457-0992
`
`28-NOV-2016
`
`20-JUL-2012
`
`14:02:26
`
`Application Type:
`
`Utility under 35 USC111(a)
`
`Payment information:
`
`Submitted with Payment
`
`Payment Type
`
`Payment was successfully received in RAM
`
`yes
`
`CARD
`
`$1700
`
`RAM confirmation Number
`
`112916INTEFSW14032600
`
`Deposit Account
`
`Authorized User
`
`190741
`
`Christine Arthur
`
`The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:
`37 CFR 1.17 (Patent application and reexamination processing fees)
`37 CFR 1.21 (Miscellaneous fees and charges)
`
`0442 
`
`

`

`File Listing:
`Document
`Number
`
`1
`
`Warnings:
`Information:
`
`Document Description
`
`File Name
`
`File Size(Bytes)/
`Message Digest
`
`Multi
`Part /.zip
`
`Pages
`(ifappl.)
`
`245161
`
`rceids.pdf
`
`yes
`
`7
`
`a6b73ea014c20bSb86f6327612b3fe1cd19
`2e9eb
`
`Multipart Description/PDF files in .zip description
`
`Document Description
`
`Start
`
`End
`
`Request for Continued Examination (RCE)
`
`Transmittal Letter
`
`Information Disclosure Statement (IDS) Form (SB08)
`
`3
`
`5
`
`7
`
`1
`
`4
`
`6
`
`77843
`
`2
`
`Non Patent Literature
`
`toole2002.pdf
`
`no
`
`7
`
`Warnings:
`Information:
`
`c70337f8aec67eb6cdf1f41477645405053 c
`0c21
`
`7295311
`
`3
`
`Non Patent Literature
`
`Marty1996.pdf
`
`no
`
`4
`
`Warnings:
`Information:
`
`050613821102d409c0ad0da289a45d6fe93
`1183e
`
`327689
`
`4
`
`Non Patent Literature
`
`estradermjune2004.pdf
`
`no
`
`22
`
`Warnings:
`Information:
`
`1d97460ef7b258eaf4b26e416aef8d93dd1 e
`dcac
`
`522915
`
`5
`
`Non Patent Literature
`
`vivelle2004.pdf
`
`no
`
`28
`
`bedSc72638aff66dSb0122934eb17e6a87d
`1a437
`
`0443 
`
`

`

`Warnings:
`Information:
`
`6
`
`Non Patent Literature
`
`vivelledot2004.pdf
`
`no
`
`28
`
`391153
`
`Warnings:
`Information:
`
`e91f07c4d292cS18223c7e77c6e7fSa77b8f
`cdS8
`
`275161
`
`7
`
`Non Patent Literature
`
`climara2007.pdf
`
`no
`
`23
`
`Warnings:
`Information:
`
`2ba61920dd4d73a49f6fb4d41 bcbfe26301
`42296
`
`322583
`
`8
`
`Non Patent Literature
`
`menostar2004.pdf
`
`no
`
`28
`
`Warnings:
`Information:
`
`818aaf0be23f41cea4bd2dS3eaa23d4da1f9
`1b4a
`
`1333321
`
`9
`
`Non Patent Literature
`
`alora2005.pdf
`
`no
`
`29
`
`Warnings:
`Information:
`
`3150b28ac9894d475dc8d1b1cef0578a7ba
`aOSaf
`
`934392
`
`10
`
`Non Patent Literature
`
`esclim98.pdf
`
`no
`
`19
`
`Warnings:
`Information:
`
`6ae80f7cc7ce83f0531c33289500eeff0b71e
`423
`
`30373
`
`1 1
`
`Fee Worksheet (SB06)
`
`fee-info.pdf
`
`no
`
`2
`
`62c13ec7b0cc5c97fa0bf42d451c06e96e8d
`5e71
`
`Warnings:
`Information:
`
`Total Files Size (in bytes):
`
`11755902
`
`0444
`
`

`

`This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents,
`characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a
`Post Card, as described in MPEP 503.
`
`New Applications Under 35 U.S.C. Ill
`If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR
`1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this
`Acknowledgement Receipt will establish the filing date of the application.
`
`National Stage of an International Application under 35 U.S.C. 371
`If a timely submission to enter the national stage of an international application is compliant with the conditions of 35
`U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a
`national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
`
`New International Application Filed with the USPTO as a Receiving Office
`If a new international application is being filed and the international application includes the necessary components for
`an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number
`and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning
`national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of
`the application.
`
`0445 
`
`

`

`SjS^igN
`
`£3 9/
`i
`i
`$
`
`l!
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`DX 1450
`P.O. Bo
`dria, Virginia 22313-1450
`Alexan
`to.gov www.usp
`
`
`NOTICE OF ALLOWANCE AND FEE(S) DUE
`
`12/09/2016
`
`22428
`7590
`Foley & Lardner LLP
`3000 K STREET N.W.
`SUITE 600
`WASHINGTON, DC 20007-5109
`
`EXAMINER
`
`JAVIER, MELISSA L
`
`ART UNIT
`
`1611
`
`PAPER NUMBER
`
`DATE MAILED: 12/09/2016
`
`APPLICATION NO.
`
`FILING DATE
`
`FIRST NAMED INVENTOR
`
`ATTORNEY DOCKET NO.
`
`CONFIRMATION NO.
`
`07/20/2012
`Juan Mantelle
`13/553,972
`TITLE OF INVENTION: TRANSDERMAL ESTROGEN DEVICE AND DELIVERY
`
`041457-0992
`
`3635
`
`APPLN. TYPE
`
`ENTITY STATUS
`
`ISSUE FEE DUE
`
`PUBLICATION FEE DUE PREV. PAID ISSUE FEE
`
`TOTAL FEE(S) DUE
`
`nonpro visional
`
`UNDISCOUNTED
`
`$960
`
`$0
`
`$0
`
`$960
`
`DATE DUE
`
`03/09/2017
`
`THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT.
`PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS.
`THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON
`PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.
`THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE
`MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED.
`THIS
`STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES
`NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION.
`IF AN ISSUE FEE HAS
`PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM
`WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW
`DUE.
`
`HOW TO REPLY TO THIS NOTICE:
`
`I. Review the ENTITY STATUS shown above. If the ENTITY STATUS is shown as SMALL or MICRO, verify whether entitlement to that
`entity status still applies.
`If the ENTITY STATUS is the same as shown above, pay the TOTAL FEE(S) DUE shown above.
`If the ENTITY STATUS is changed from that shown above, on PART B - FEE(S) TRANSMITTAL, complete section number 5 titled
`"Change in Entity Status (from status indicated above)".
`For purposes of this notice, small entity fees are 1/2 the amount of undiscounted fees, and micro entity fees are 1/2 the amount of small entity
`fees.
`
`II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office
`(USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b"
`of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a
`request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing
`the paper as an equivalent of Part B.
`III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to
`Mail Stop ISSUE FEE unless advised to the contrary.
`IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of
`maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.
`
`PTOL-85 (Rev. 02/11)
`
`Page 1 of 3
`
`0446 
`
`

`

`PART B - FEE(S) TRANSMITTAL
`Complete and send this form, together with applicable fee(s), to: Mail Mail Stop ISSUE FEE
`Commissioner for Patents
`P.O. Box 1450
`Alexandria, Virginia 22313-1450
`or Fax (571)-273-2885
`INSTRUCTIONS: This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where
`appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as
`indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for
`maintenance fee notifications.
`
`CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)
`
`12/09/2016
`
`22428
`7590
`Foley & Lardner LLP
`3000 K STREET N.W.
`SUITE 600
`WASHINGTON, DC 20007-5109
`
`Note: A certificate of mailing can only be used for domestic mailings of the
`Fee(s) Transmittal. This certificate cannot be used for any other accompanying
`papers. Each additional paper, such as an assignment or formal drawing, must
`have its own certificate of mailing or transmission.
`
`Certificate of Mailing or Transmission
`I hereby certify that this Fee(s) Transmittal is being deposited with the United
`States Postal Service with sufficient postage for first class mail in an envelope
`addressed to the Mail Stop ISSUE FEE address above, or being facsimile
`transmitted to the USPTO (571) 273-2885, on the date indicated below.
`
`(Depositor's name)
`
`(Signature)
`
`(Date)
`
`APPLICATION NO.
`
`FILING DATE
`
`FIRST NAMED INVENTOR
`
`ATTORNEY DOCKET NO.
`
`CONFIRMATION NO.
`
`07/20/2012
`Juan Mantelle
`13/553,972
`TITLE OF INVENTION: TRANSDERMAL ESTROGEN DEVICE AND DELIVERY
`
`041457-0992
`
`3635
`
`APPLN. TYPE
`
`ENTITY STATUS
`
`ISSUE FEE DUE
`
`nonprovisional
`
`UNDISCOUNTED
`
`$960
`
`PUBLICATION FEE DUE PREV. PAID ISSUE FEE
`$0
`$0
`
`TOTAL FEE(S) DUE
`
`$960
`
`DATE DUE
`
`03/09/2017
`
`EXAMINER
`
`ART UNIT
`
`CLASS-SUBCLASS
`
`JAVIER, MELISSA L
`
`1611
`
`424-487000
`
`1. Change of correspondence address or indication of "Fee Address" (37
`2. For printing on the patent front page, list
`CFR 1.363).
`(1) The names of up to 3 registered patent attorneys
`Q Change of correspondence address (or Change of Correspondence
`or agents OR, alternatively,
`Address form PTO/SB/122) attached.
`(2) The name of a single firm (having as a member a
`Q "Fee Address" indication (or "Fee Address" Indication form
`registered attorney or agent) and the names of up to
`2 registered patent attorneys or agents. If no name is
`PTO/SB/47; Rev 03-02 or more recent) attached. Use of a Customer
`listed, no name will be printed.
`Number is required.
`3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)
`PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for
`recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.
`(A) NAME OF ASSIGNEE
`(B) RESIDENCE: (CITY and STATE OR COUNTRY)
`
`2-
`
`3
`"
`
`1
`
`Please check the appropriate assignee category or categories (will not be printed on the patent):
`
`4a. The following fee(s) are submitted:
`Q Issue Fee
`Q Publication Fee (No small entity discount permitted)
`Q Advance Order - # of Copies
`
`Q Individual Q Corporation or other private group entity Q Government
`4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above)
`Q A check is enclosed.
`Q Payment by credit card. Form PTO-2038 is attached.
`Q The director is hereby authorized to charge the required fee(s), any deficiency, or credits any
`(enclose an extra copy of this form).
`overpayment, to Deposit Account Number
`
`5. Change in Entity Status (from status indicated above)
`Q Applicant certifying micro entity status. See 37 CFR 1.29
`Q Applicant asserting small entity status. See 37 CFR 1.27
`Q Applicant changing to regular undiscounted fee status.
`
`NOTE: Absent a valid certification of Micro Entity Status (see forms PTO/SB/15A and 15B), issue
`fee payment in the micro entity amount will not be accepted at the risk of application abandonment.
`NOTE: If the application was previously under micro entity status, checking this box will be taken
`to be a notification of loss of entitlement to micro entity status.
`NOTE: Checking this box will be taken to be a notification of loss of entitlement to small or micro
`entity status, as applicable.
`NOTE: This form must be signed in accordance with 37 CFR 1.31 and 1.33. See 37 CFR 1.4 for signature requirements and certifications.
`
`Authorized Signature
`
`Typed or printed name
`
`PTOL-85 Part B (10-13) Approved for use through 10/31/2013.
`
`OMB 0651-0033
`
`Page 2 of 3
`
`Date
`
`Registration No.
`
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COM^^^E 
`
`

`

`SjS^igN
`
`£3 9/
`i
`i
`$
`
`l!
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`UNITED STATES DEPARTMENT OF COMMERCE
`United States Patent and Trademark Office
`Address: COMMISSIONER FOR PATENTS
`DX 1450
`P.O. Bo
`dria, Virginia 22313-1450
`Alexan
`to.gov www.usp
`
`
`APPLICATION NO.
`
`FILING DATE
`
`FIRST NAMED INVENTOR
`
`ATTORNEY DOCKET NO.
`
`CONFIRMATION NO.
`
`13/553,972
`
`07/20/2012
`
`Juan Mantelle
`
`041457-0992
`
`3635
`
`12/09/2016
`
`22428
`7590
`Foley & Lardner LLP
`3000 K STREET N.W.
`SUITE 600
`WASHINGTON, DC 20007-5109
`
`EXAMINER
`
`JAVIER, MELISSA L
`
`ART UNIT
`
`1611
`
`PAPER NUMBER
`
`DATE MAILED: 12/09/2016
`
`Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)
`(Applications filed on or after May 29, 2000)
`
`The Office has discontinued providing a Patent Term Adjustment (PTA) calculation with the Notice of Allowance.
`
`Section 1(h)(2) of the AIA Technical Corrections Act amended 35 U.S.C. 154(b)(3)(B)(i) to eliminate the
`requirement that the Office provide a patent term adjustment determination with the notice of allowance. See
`Revisions to Patent Term Adjustment, 78 Fed. Reg. 19416, 19417 (Apr. 1, 2013). Therefore, the Office is no longer
`providing an initial patent term adjustment determination with the notice of allowance. The Office will continue to
`provide a patent term adjustment determination with the Issue Notification Letter that is mailed to applicant
`approximately three weeks prior to the issue date of the patent, and will include the patent term adjustment on the
`patent. Any request for reconsideration of the patent term adjustment determination (or reinstatement of patent term
`adjustment) should follow the process outlined in 37 CFR 1.705.
`
`Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of
`Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be
`directed to the Customer Service Center of the Office of Patent Publication at l-(888)-786-0101 or (571)-272-4200.
`
`PTOL-85 (Rev. 02/11)
`
`Page 3 of 3
`
`0448
`
`

`

`OMB Clearance and PRA Burden Statement for PTOL-85 Part B
`
`The Paperwork Reduction Act (PRA) of 1995 requires Federal agencies to obtain Office of Management and
`Budget approval before requesting most types of information from the public. When OMB approves an agency
`request to collect information from the public, OMB (i) provides a valid OMB Control Number and expiration
`date for the agency to display on the instrument that will be used to collect the information and (ii) requires the
`agency to inform the public about the OMB Control Number's legal significance in accordance with 5 CFR
`1320.5(b).
`
`The information collected by PTOL-85 Part B is required by 37 CFR 1.311. The information is required to obtain
`or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is
`governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete,
`including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary
`depending upon the individual case. Any comments on the amount of time you require to complete this form
`and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and
`Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT
`SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box
`1450, Alexandria, Virginia 22313-1450. Under the Paper